Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists

被引：24
|
作者：
Bui, Kim Tam [1 ]
Cooper, Wendy A. [2 ,3 ,4 ]
Kao, Steven [1 ,4 ]
Boyer, Michael [1 ,4 ]
机构：
[1] Chris OBrien Lifehouse, 119-143 Missenden Rd Camperdown, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[3] Western Sydney Univ, Sch Med, Sydney, NSW 2560, Australia
[4] Royal Prince Alfred Hosp, 50 Missenden Rd Camperdown, Camperdown, NSW 2050, Australia
来源：
JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 08期
关键词：
personalized therapy; non-small cell; lung cancer; targeted therapy; mutation; rearrangement; RANDOMIZED PHASE-III; PLATINUM-BASED CHEMOTHERAPY; OPEN-LABEL; 1ST-LINE TREATMENT; DOUBLE-BLIND; MAINTENANCE THERAPY; EGFR MUTATIONS; SINGLE-ARM; CARBOPLATIN-PACLITAXEL; ACQUIRED-RESISTANCE;
D O I：
10.3390/jcm7080192
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific anti-cancer therapies to improve patient outcomes. New targeted molecular treatments are constantly being developed and evaluated as a means to improve efficacy, overcome resistance, or minimise toxicity. This review article summarises the current evidence for the efficacy, resistance mechanisms, and safety of targeted molecular treatments against specific mutations in NSCLC.
引用
收藏
页数：18
相关论文
共 50 条
  • [21] Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials
    Yu, Le
    Yang, Ruoyi
    Long, Zeng
    Tao, Qingxiu
    Liu, Bin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [22] Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives
    Zhang, Hang
    Zhang, Yingying
    Zhu, Yingying
    Dong, Tian
    Liu, Zheng
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [23] Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)
    Kumarakulasinghe, Nesaretnam Barr
    van Zanwijk, Nico
    Soo, Ross A.
    RESPIROLOGY, 2015, 20 (03) : 370 - 378
  • [24] Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
    Dienstmann, Rodrigo
    Martinez, Pablo
    Felip, Enriqueta
    ONCOTARGET, 2011, 2 (03) : 165 - 177
  • [25] Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer
    Shroff, Girish S.
    de Groot, Patricia M.
    Papadimitrakopoulou, Vassiliki A.
    Truong, Mylene T.
    Carter, Brett W.
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2018, 56 (03) : 485 - +
  • [26] Update 2020: Management of Non-Small Cell Lung Cancer
    Alexander, Mariam
    Kim, So Yeon
    Cheng, Haiying
    LUNG, 2020, 198 (06) : 897 - 907
  • [27] Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
    Wu, Jiajia
    Lin, Zhenghong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [28] Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
    Moya-Horno, Irene
    Viteri, Santiago
    Karachaliou, Niki
    Rosell, Rafael
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [29] Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer
    Rivera-Concepcion, Joel
    Uprety, Dipesh
    Adjei, Alex A.
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 315 - 329
  • [30] CURRENT STATUS OF TARGETED THERAPY IN NON-SMALL CELL LUNG CANCER
    Parums, D. V.
    DRUGS OF TODAY, 2014, 50 (07) : 503 - 525
12345